Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist inChina - TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis inEurope by the end of the year BOSTON and SEONGNAM, South Korea, July 5, 2023 /P...

2023-07-05 20:00 1667

BGI CEO Yin Ye Advocates for Global Technology Sharing

SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference inRiyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity. "We ...

2023-07-05 14:17 1651

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evalu...

2023-07-04 21:16 2141

Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer

Highlights * FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer * Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial * A total of 383 prostate cancer patients to take part ...

2023-07-04 20:55 2125

China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy

-- pitolisant is the first and only treatment drug approved in mainland China for narcolepsy. SHANGHAI, July 4, 2023 /PRNewswire/ -- RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chinese National Med...

2023-07-04 20:42 1819

Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology

- Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists' chest X-ray analysis performance SEOUL, South Korea, July 3, 2023 /PRNewswire/ -- Findings from a recent study demonstrate that medical AI solutions with onl...

2023-07-03 21:00 2019

Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration

SHANGHAI and BOSTON, July 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...

2023-07-03 19:00 1477

Henlius Forecasts Profit in 1H 2023

Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...

2023-07-03 17:49 2186

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease

SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health ...

2023-07-03 08:00 2599

Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally

* Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials inChina. * BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications overseas and clinical trial materials supply. SHANGHAI, Ju...

2023-06-30 20:15 2310

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 29, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2023-06-29 21:26 2182

Jowell Global Ltd. Granted Extension to Meet Nasdaq Minimum Bid Price Requirement

SHANGHAI, June 29, 2023 /PRNewswire/ -- Jowell Global Ltd. ("Jowell Global" or the "Company") (NASDAQ: JWEL), one of the leading cosmetics, health and nutritional supplements, and household products e-commerce platforms inChina, today announced that, onJune 27, 2023, the Company received a writte...

2023-06-29 20:00 3531

HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial

* Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%). * Significant overall survival advantage, with a 46% reduction in the risk of death. * Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further Kap...

2023-06-29 19:00 1661

Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer

BEIJING, KYOTO and BOSTON, June 29, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G...

2023-06-29 16:31 1667

Clarity establishes a US Center of Excellence for Targeted Copper Theranostics

SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a ...

2023-06-28 20:58 2034

Flat Medical Expands Leadership Team to Manage Growth in Europe and the United States

TAIPEI, June 28, 2023 /PRNewswire/ -- Flat Medical Co. Ltd., a leading MedTech company specializing in safety solutions for anesthesia and critical care, is pleased to announce the appointment of two executives who will spearhead the company's expansion inEurope and America. Jan Wormmeester has b...

2023-06-28 20:30 1653

Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development

SHANGHAI, June 28, 2023 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as Sanyou) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (hereinafter referred to asHuadong Medicine), signed...

2023-06-28 20:00 1766

Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

* CBL-514 is the only non-invasive product that can improve 1-level of cellulite severity two weeks after a single treatment. * The highest dose of CBL-514 treatment demonstrated the best efficacy, 87.5% of thighs achieved at least 1-level improvement in cellulite severity two weeks after CBL...

2023-06-28 18:30 1647

Quhuo Creates a Warm and Supportive Work Environment for Deaf-Mute Riders

BEIJING, June 28, 2023 /PRNewswire/ -- "I joined Quhuo as a delivery rider in 2020 and have been working for three years now, and joining Quhuo has been a great blessing for me." Zhang Xueqing expresses immense gratitude for becoming a delivery rider forQuhuo Limited

2023-06-28 18:00 2000

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

HONG KONG, June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltdtogether with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"), a non-wholly owned subsidiary of Company, has received a drug registration approval from the Natio...

2023-06-28 09:57 1588

1 ... 50 51 525354 55 56 ... 255